Prescription Required 
Formulation : 
Description
Indications
The combination of netupitant and palonosetron is indicated for the prevention of nausea and vomiting induced by cancer chemotherapy. Netupitant belongs to the pharmacological class of neurokinin (NK1) antagonists, which function by inhibiting the action of neurokinin, a endogenous substance in the brain known to elicit nausea and vomiting. Palonosetron is classified as a 5-HT3 receptor antagonist and acts by blocking serotonin, an endogenous substance in the body that triggers the sensation of nausea and vomiting.
Uses and Dosage
The oral formulation of netupitant and palonosetron is available in capsule form. Generally, it is administered approximately one hour before the commencement of chemotherapy, either with or without food.
The medication should be taken exactly as prescribed, neither more nor less frequently, and not in greater or lesser quantities than directed by your healthcare provider.
Side Effects
Some side effects may occur that usually do not need medical attention:
- headache
- stomach pain
- heartburn
- constipation
- weakness
- redness of the skin
Inform your healthcare provider immediately if you experience any serious side effects:
- hives
- rash
- itching
- difficulty breathing or swallowing
- shortness of breath
- dizziness, lightheadedness, and fainting
- fast, slow or irregular heartbeat
- agitation
- hallucinations (seeing things or hearing voices that do not exist)
- fever
- flushing
- excessive sweating
- confusion
- nausea, vomiting, and diarrhea
- loss of coordination
- stiff or twitching muscles
- seizures
- coma (loss of consciousness)
Caution
Prior to initiating treatment with this product, inform your healthcare provider or pharmacist of any allergies to netupitant, palonosetron, other anti-emetic serotonin antagonists (e.g., ondansetron), or any other allergies you may have. The formulation may contain inactive constituents that can elicit allergic reactions or other complications.
Disclose your medical history, specifically any history of kidney disease, or liver disease, to your physician or pharmacist before commencing treatment with this medication.
The administration of this medication during pregnancy should only occur if it is unequivocally necessary. Discuss the potential risks and benefits with your doctor.
It remains unclear whether this product passes into breast milk. Consult with your physician before breastfeeding.
Form and Strength
Akynzeo is available in the following forms and strengths:
-
Akynzeo capsule:
- 300mg/0.5mg
FAQ
Do I have to take Akynzeo with food?
You can take Akynzeo with or without food.
Can Akynzeo be used in children?
No, it’s not known if Akynzeo is safe or effective in children younger than 18 years old.
